Form 4: Ionis Pharmaceuticals EVP Shannon L. Devers Reports Stock Option Grant

Shannon L. Devers, EVP and Chief Human Resources Officer of Ionis Pharmaceuticals, reports the grant of stock options.

Summary

• On September 29, 2024, Shannon L. Devers, EVP and Chief Human Resources Officer of Ionis Pharmaceuticals, received a grant of 15,040 non-qualified stock options with an exercise price of $40.85.
• The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• The options vest as to 0 shares on 09/29/2024.
• 25% of the shares subject to the option will vest and become exercisable on 09/29/2025.
• The remaining shares will vest in 36 equal monthly installments over the next 3 years.
• Following the transaction, Devers directly owns 15,040 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating a stable and ongoing operation. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparable companies like Alnylam Pharmaceuticals and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could incentivize the executive to improve company performance, benefiting shareholders.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates